| Name | fosinopril |
|---|---|
| Synonyms |
[1[S^<*>^ (R^<*>^)],2α,4β]-4-Cyclohexyl-1-[[[2-methyl-1-(1-oxopropoxy)-propoxy](4-phenylbutyl)phosphinyl]acetyl]-L-proline
Fosinopril //BP Stil FOSINOPRIL,(4S)-4-CYCLOHEXYL-1-[(RS)-2-METHYL-1-(PROPIONYLOXY)PROPOXY]-(4-PHENYLBUTYL)PHOSPHINYLACETYL-L-PROLINE Fosenopril/((4S)-4-Cyclohexyl-1-[(R)-[(S)-1-hydroxy-2-methylpropoxy](4-phenylbutyl)phosphinyl]acetyl-D-proline Propionate (Ester) Hemibium Salt Sesquihydrate) Staril MFCD00870759 Secorvas fosenopril (2S,4S)-4-cyclohexyl-1-[2-[[(1S)-2-methyl-1-(1-oxopropoxy)propoxy]-(4-phenylbutyl)phosphoryl]-1-oxoethyl]-2-pyrrolidinecboxylic acid 4β-Cyclohexyl-1-[[[(S)-2-methyl-1-(1-oxopropoxy)propoxy](4-phenylbutyl)phosphinyl]acetyl]-L-proline (2S,4S)-4-cyclohexyl-1-{2-[(S)-[(1S)-2-Methyl-1-(propanoyloxy)propoxy](4-phenylbutyl)phosphoryl]acetyl}pyrrolidine-2-cboxylic acid (2S,4S)-4-cyclohexyl-1-(2-((2-Methyl-1-(propionyloxy)propoxy)(4-phenylbutyl)phosphoryl)acetyl)pyrrolidine-2-cboxylic acid L-Proline, 4-cyclohexyl-1-[2-[(R)-[(1S)-2-methyl-1-(1-oxopropoxy)propoxy](4-phenylbutyl)phosphinyl]acetyl]-, (4S) 4-cyclohexyl-1-[2-[(2-methyl-1-propanoyloxypropoxy)-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-cboxylic acid 4-cyclohexyl-1-[2-[(2-methyl-1-propanoyloxy-propoxy)-(4-phenylbutyl)phosphoryl]acetyl] C13942000 Fosinopril L-Proline, 4-cyclohexyl-1-(R)-(1S)-2-methyl-1-(1-oxopropoxy)propoxy(4-phenylbutyl)phosphinylacetyl-, (4S) SQ-28555 |
| Description | Fosinopril (SQ28555) is the ester prodrug of an angiotensin-converting enzyme (ACE) inhibitor with the IC50 value of 0.18 μM[1]. Fosinopril demonstrates a non-competitive inhibition effect on ACE activity with a Ki value of 1.675 μM[2]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 0.18 μM; Ki: 1.675 μM |
| In Vitro | Fosinopril (0, 1, 10, 33, 100μM; 30 min) partially inhibits the cosedimentation of liposomes and recombinant LPLA2[1]. Fosinopril (250 nM) shows no inhibition of the soluble esterase activity of LPLA2[1]. Fosinopril (0.372, 0.744, 1.116 μM) displays a non-competitive inhibition effect on ACE activity with a Ki value of 1.675 μM[2]. |
| In Vivo | Fosinopril (orally; 4.67 mg/kg; 4 weeks) downregulates the creatine kinase (CK) and lactate dehydrogenase (LDH) levels and against cardiac dysfunction and structural alteration[3]. Fosinopril (orally; 4.67 mg/kg; 4 weeks) suppresses cleaved-caspase 3 expression and myocardial apoptosis in AMI rat model[3]. Animal Model: HF post-acute myocardial infarction (AMI) rat model (SPF-grade Sprague-Dawley (SD) rats, 265 ± 15 g) [3] Dosage: 4.67 mg/kg Administration: p.o.; 4 weeks Result: Against cardiac dysfunction and structural alteration and suppressed apoptosis. |
| References |
| Density | 1.173 g/cm3 |
|---|---|
| Boiling Point | 705.7ºC at 760 mmHg |
| Melting Point | 149-153ºC |
| Molecular Formula | C30H46NO7P |
| Molecular Weight | 563.66300 |
| Flash Point | 380.6ºC |
| Exact Mass | 563.30100 |
| PSA | 120.02000 |
| LogP | 6.05920 |
| Index of Refraction | 1.531 |
| Water Solubility | Insoluble |
| HS Code | 2942000000 |
|---|
| HS Code | 2942000000 |
|---|